Background: Co-morbidities are associated with increasing risk of mortality, hospitalizations and costs of
Introduction
Chronic obstructive pulmonary disease (COPD) is a common disease that severely threatens human health. As World Health Organization (WHO) has predicted, social and economic burden of COPD will rise to the fifth and COPD will become the third leading cause of death worldwide by 2030.
(1) COPD is a complex syndrome with pulmonary and extra-pulmonary manifestations. In the recent years, clinicians also proved that the heterogeneity of COPD is associated with different clinical outcomes including symptoms, exacerbations, responses to recommended therapy, decline of lung function and death. (2) Generally, phenotype is any observed quality of an organism, like its morphology, development or behavior, as opposed to its genotype, which is the inherited instructions it carries, which may or may not be expressed. (3) However, only phenotypes associated with symptoms, prognosis, progression and response to therapy are relevant in clinical practice. So, the term clinical phenotype in the field of COPD is defined as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes symptoms, exacerbations, response to treatment, speed of progression of the disease or death. (3) Adding to lung involvement, a lot of "co-morbidities" may present in patients with COPD such as cardiovascular disease, metabolic dysfunctions, and depressive disorders are more commonly present. A number of potential mechanisms linking COPD and co-morbidities have been hypothesis: The pro-inflammatory cascade, (4, 5, 6) increased oxidative stress, (7) increased arterial stiffness, (8, 9) catabolic state, (10) and sedentary lifestyle. (11) Patients with COPD are often "multi-system diseased patients," presenting with different clinical pictures, with a poorer quality of life and outcomes, (12) and a high disease-related burden. (13, 14) Therefore, the phenotype should be able to classify the patients into subgroups with a prognostic value that allow for determining the best therapy in order to achieve better clinical results.
Patients and Methods
This prospective study of phenotypes of chronic obstructive pulmonary disease and its co-morbidities 2-Young aged patients < 40 years.
All Patients in the Study Investigated Thorough
Medical History Including
• Age, sex, occupation, residence.
• Smoking history , type of smoking , smoking index.
• History of exposure to biomass fuel, and other special habits .
• History of chronic cough.
• History of exertional dyspnea using (mMRC) dyspnea scale (Modified Medical Research Council)
Questionnaire for Assessing the Severity of breathlessness.
• History of other symptoms orthopnea, chest pain, fever, heamptosis, wheezes, palpation, epigastric pain, cyanosis, anorexia, loss of weight, muscle and bone pain.
• Family history.
• History of exacerbation, previous hospitalization and ICU admission and classification of exacerbation C. Severe (patients require hospitalization or visit emergency room) may be also associated with acute respiratory failure .
• Quality of life determined using the St. George's Respiratory
Questionnaire for COPD patients (SGRQ). (15) Using • BODEx index (BMI, FEV1, dyspnea and exacerbations) for assessment the COPD severity and predicts mortality, hospitalization, and exacerbation frequency .
• CAT score (COPD assessment test also for assessment of COPD severity.
Thorough Clinical Examination Including
• General examination (pulse, Blood pressure, temperature, respirtratory rate, JVP, lower limb edema, lymph node)
• Chest examination (inspection, palpation, percussion and auscultation).
Investigations Including
• Chest x ray (postero-anterior) .
• Abdominal ultrasonography.
• 
• Arterial blood gases (ABG):-is a test that measures the partial pressure of arterial oxygen (PaO2) and carbon dioxide (PaCO2), oxygen saturation (SO2) and acidity (PH) in arterial blood. (ABL800) .
• Electrocardiography (ECG), and Echocardiography.
• • Computerized tomography (CT) scan for chest.
Statistical Analysis
Analysis of data was done by IBM computer using SPSS (statistical program for social science version 24.0) as follows:
• Description of quantitative variables as mean, SD and range.
• There was significance difference in BODEx index (BMI, FEV1,dyspnea and exacerbations) and CAT score of different COPD phenotypes P-value 0.020 and <0.001 respectively. As shown in figure 1, 2
The most common co-morbidities in all studied subjects was gastritis 58.2% of studied subjects, 
Discussion
COPD is a major cause of chronic morbidity and mortality throughout the world; many people suffer from this disease for years, and die prematurely from it or its complications. Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population. The most common co-morbidity present in our studied cases was gastritis followed by cor-pulmonale and hypertension and this is inconsistent with (Gianna et al.,). (21) In our study there was no significance difference in number of exacerbation in last year of different COPD phenotypes, this was in agreement with ( Jose´ Luis et al.,) (20) In our study there was significance difference between number of hospitalization in last year between different COPD phenotypes compared with (Jose´Luis et al.,) study there was no significance difference between number of hospitalization in last year. In our study there was no significance difference in number of ICU admission between phenotype, this was agreed with
Beeh, Glaab et al., 2013) (22) and ( Jose´Luis et al.,) (20) .
In Osteoporosis was founded more in COPD with bronchiactasis, Emphysema and Frequent excerbator phenotypes with significant difference and this was in agreement with Gianna et al. (21) Our results showed that the highest association of co-morbidities is seen mostly in patients with severe COPD phenotypes. These findings were in agreement with Mahboub et al., (23) and Dal Negro et al., (24) who reported an association between the prevalence of comorbidity and COPD severity measured by a COPD assessment test score >10 or by Global Initiative on
Obstructive Lung Disease stages, respectively, and disagreement with with findings of Watz et al. (25) The co-morbidity related to heart dysfunction in frequent excerbator and emphysema phenotypes are particularly important predictors of increased risk of death in patients with COPD and indicate the importance of cardiovascular disease as a factor contributing to COPD mortality and this was consistent with Zielinski et al., (26) 
Conclusion
The presence of significant co-morbidities is one of the most important modifying risk factors for severity in COPD. They contribute to the overall severity in individual patients, have a major impact on quality of life, increase the risk of certain causes of mortality and of all-cause mortality and are major causes of hospitalization , Co-morbidities can be associated with any clinical phenotype. But we found that distribution of Co morbidities not much different between these phenotypes, gastritis was the most frequent co-morbidity in all phenotypes, then systemic hypertension and cor-pulmonale. But diabetes mellitus was more common in ACOS phenotypes, depression was more common in frequent excerbator phenotype.
